Weekly Rundown: Small-Cap Stocks with Upcoming Catalysts (June 16–20)

We’ve analyzed the latest company announcements and filings to spotlight key developments among small-cap stocks, along with upcoming investor events. Our goal is to deliver timely updates that keep you in the loop and help uncover new opportunities. Here’s what’s on our radar for the week of June 16–20.

Companies Participating in the 2025 BIO International Convention (June 16–19, 2025, Boston, MA):

PCSA GRCE GNPX EVAX LEXX APVO

—-------------------------------------------------------------

OCGN OKYO TELO NNVC MIRA LGVN

—-------------------------------------------------------------

SCNI LSTA AZTR VANI HOWL TLSA

—-------------------------------------------------------------

MAIA OGEN EDSA ANRO MDCX

Companies Participating in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (June 16–17, 2025):

NRXP RVPH LGVN ANRO ATAI VYGR GANX IMAB

Companies Presenting at the Emerging Growth Virtual Conference (Tuesday, June 17, 2025):

URG OMEX

Companies Presenting at the Singular Research Summer Solstice Conference (June 18, 2025):

DAIO CURI

Companies Presenting at the ESMO Gynaecological Cancers Congress 2025 (June 19–21, 2025 | Vienna, Austria):

ANIX > Phase 1 trial of autologous T-cells engineered to target FSHR in recurrent ovarian cancer (OVCA)

IMNN > Poster on IMNN-001 immune biomarker data from Phase 2 OVATION 2 Study in newly diagnosed advanced ovarian cancer

Companies Presenting at the EACR 2025 Annual Congress (June 16–19, 2025 | Lisbon, Portugal):

CGEN > Presentation on immune evasion and immunotherapy resistance in TNBC subtypes – June 18

PPBT > Presentation on CAPTN-3 platform for T cell and NK cell engagers – June 17

Companies Presenting at the ADA 85th Scientific Sessions (June 20–23, 2025 | Chicago, IL):

GUTS > Single-dose GLP-1 gene therapy prevents obesity/diabetes in high-fat–fed mice – June 22

SANA > Podium: First-in-human islet transplant using HIP tech without immunosuppression – June 23

MNKD > INHALE-1 trial results in youth with Afrezza inhalation insulin – June 21–22

MTVA > Preclinical data on DA-1241, a novel GPR119 agonist – June 22

GCTK > Safety & performance data from 1st-in-human CBGM trial – June 21–22

GNPX > Preclinical data and research on novel diabetes gene therapy – June 21 & 23

SENS > Company to discuss FDA-approved Eversense® 365 CGM system – June 21

SKYE > Preclinical data and market insights on development program – Date not specified

Other Companies with Key Catalysts This Week:

VERU > Company Participating in the BTIG Obesity Health Forum (Virtual | June 18, 2025)

GALT > The company will host a virtual KOL event on June 16, 2025, focusing on MASH cirrhosis and portal hypertension.

IMAB > Management team will participate in the H.C. Wainwright "HCW@Home" Series, being held virtually on Tuesday, June 17, 2025.

PHUN > Phunware will participate in the 2025 HITEC® conference (June 16–19), showcasing its mobile hospitality solution and new AI features at Booth #2233, with a team-led discussion on next-gen mobile apps scheduled for June 18 at Tutorial Stage A.

HIT > CEO Tim Johnson and CFO Julia Qian will represent the company as a Gold Sponsor at the American Trust Investment Services National Conference 2025, to be held June 16–18, 2025.

SILO > The upcoming U.S. Patent No. 12,329,726, expected to be issued on June 17, 2025, will further strengthen Silo’s IP protection for SPC-15, its intranasal treatment for PTSD.

PDSB > The company will host a virtual KOL event on Tuesday, June 17, 2025, featuring Drs. Kevin Harrington and Katharine Price to discuss the unmet need and treatment landscape for recurrent/metastatic HPV16-positive HNSCC.

HUYA > The company announced that the NYSE has set July 1, 2025, as the ex-dividend date for its $1.47 per share cash dividend, part of the 2025-2027 Dividend Plan announced on March 18, 2025. Since the dividend exceeds 25% of the ADS price on the announcement date, the ex-dividend date will be the first business day after the expected June 30, 2025 payment date. The record date is June 17, 2025 (the "due bill period"), and if you sell anytime from June 17 through June 30, you will lose the right to the dividend—even if you were on record as a shareholder on June 17.

LVO > The company announced a partnership with new combat discipline BKFC Ice Wars for their upcoming "Battle of the Border" USA vs. Canada event, with LiveOne hosting the livestream on June 18, 2025.

XHLD > On June 18, 2025, at 2:00 PM ET, TEN Holdings’ management team will present a corporate overview and host a live Q&A during the Webull Corporate Connect Webinar, which offers public companies a chance to engage directly with Webull’s retail investor community through virtual presentations.

MYO > The Company will host its first-ever Investor & Analyst Day on Wednesday, June 18, 2025, at Myomo’s new headquarters and manufacturing facility in Burlington, Mass., providing an in-depth look at its latest innovations, strategic plans, and growth initiatives focused on empowering individuals with neuromuscular disorders through advanced wearable medical robotics.

STGW > The company announced that tennis legend Serena Williams has been added to its SPORT BEACH 2025 roster. Following the recent launch of her and her sister Venus' podcast with X, Serena will join X CEO Linda Yaccarino on Thursday, June 19 for a fireside chat at SPORT BEACH to share her vision for a new model of athlete-entrepreneur.

ADCT > Data from the LOTIS-7 Phase 1b open-label trial assessing the safety and efficacy of ZYNLONTA® combined with the bispecific antibody glofitamab (COLUMVI®) in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) patients will be presented at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, on Friday, June 20.

LCTX > The company announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) will be presented at Clinical Trials at the Summit (CTS) 2025, scheduled for June 20–21, 2025.

GAIA > The company announced "BioGeometry with Dr. Ibrahim Karim," a two-day immersive event taking place June 21–22 at the GaiaSphere Event Center in Boulder, Colorado.

OP > The company announced that, through a separate wholly-owned subsidiary, it has signed a Memorandum of Agreement to sell the 2004-built dry bulk vessel Protefs to a third party, for a sale price of US$7 million before commissions, with delivery to the buyer no later than June 17, 2025.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.